Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles

Virology

Volumn 373, Issue 1, 2008, Pages 72-84

  Phogat, S ^a   Svehla, K ^a   Tang, M ^a   Spadaccini, A ^b   Muller, J ^b   Mascola, J ^a   Berkower, I ^b   Wyatt, R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Envelope glycoproteins; gp41; HIV 1; Neutralizing antibodies; Particles

Indexed keywords

GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; HEPATITIS B SURFACE ANTIGEN; NANOPARTICLE;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; IMMUNE SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; VIRUS ENVELOPE;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEPATITIS B SURFACE ANTIGENS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; RABBITS; RECOMBINANT FUSION PROTEINS; VIRION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 40649095248     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.11.005     Document Type: Article

References (52)

1. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., and Berger E.A. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 5270 (1996) 1955-1958
2. Bachmann M.F., and Zinkernagel R.M. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 15 (1997) 235-270
3. Bachmann M.F., Kalinke U., Althage A., Freer G., Burkhart C., Roost H., Aguet M., Hengartner H., and Zinkernagel R.M. The role of antibody concentration and avidity in antiviral protection. Science 276 5321 (1997) 2024-2027
4. Berkower I., Raymond M., Muller J., Spadaccini A., and Aberdeen A. Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120. Virology 321 1 (2004) 75-86
5. Berson J.F., Long D., Doranz B.J., Rucker J., Jirik F.R., and Doms R.W. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J. Virol. 70 9 (1996) 6288-6295
6. Brown D.R., Fife K.H., Wheeler C.M., Koutsky L.A., Lupinacci L.M., Railkar R., Suhr G., Barr E., Dicello A., Li W., Smith J.F., Tadesse A., and Jansen K.U. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 22 21-22 (2004) 2936-2942
7. Brunel F.M., Zwick M.B., Cardoso R.M., Nelson J.D., Wilson I.A., Burton D.R., and Dawson P.E. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J. Virol. 80 4 (2006) 1680-1687
8. Cabral G.A., Marciano-Cabral F., Funk G.A., Sanchez Y., Hollinger F.B., Melnick J.L., and Dreesman G.R. Cellular and humoral immunity in guinea pigs to two major polypeptides derived from hepatitis B surface antigen. J. Gen. Virol. 38 2 (1978) 339-350
9. Cardoso R.M., Zwick M.B., Stanfield R.L., Kunert R., Binley J.M., Katinger H., Burton D.R., and Wilson I.A. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22 2 (2005) 163-173
10. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P.D., Wu L., Mackay C.R., LaRosa G., Newman W., Gerard N., Gerard C., and Sodroski J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85 7 (1996) 1135-1148
11. Coeffier E., Clement J.M., Cussac V., Khodaei-Boorane N., Jehanno M., Rojas M., Dridi A., Latour M., El Habib R., Barre-Sinoussi F., Hofnung M., and Leclerc C. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 19 7-8 (2000) 684-693
12. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., and Landau N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381 6584 (1996) 661-666
13. Dey B., Pancera M., Svehla K., Shu Y., Xiang S.H., Vainshtein J., Li Y., Sodroski J., Kwong P.D., Mascola J.R., and Wyatt R. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J. Virol. 81 11 (2007) 5579-5593
14. Doranz B.J., Rucker J., Yi Y., Smyth R.J., Samson M., Peiper S.C., Parmentier M., Collman R.G., and Doms R.W. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85 7 (1996) 1149-1158
15. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381 6584 (1996) 667-673
16. Eckhart L., Raffelsberger W., Ferko B., Klima A., Purtscher M., Katinger H., and Ruker F. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J. Gen. Virol. 77 Pt 9 (1996) 2001-2008
17. Ernst W., Grabherr R., Wegner D., Borth N., Grassauer A., and Katinger H. Baculovirus surface display: construction and screening of a eukaryotic epitope library. Nucleic Acids Res. 26 7 (1998) 1718-1723
18. Feng Y., Broder C.C., Kennedy P.E., and Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272 5263 (1996) 872-877
19. Fife K.H., Wheeler C.M., Koutsky L.A., Barr E., Brown D.R., Schiff M.A., Kiviat N.B., Jansen K.U., Barber H., Smith J.F., Tadesse A., Giacoletti K., Smith P.R., Suhr G., and Johnson D.A. Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particle candidate vaccines in young healthy women. Vaccine 22 21-22 (2004) 2943-2952
20. Frazer I.H. Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev., Immunol. 4 1 (2004) 46-54
21. Grundner C., Mirzabekov T., Sodroski J., and Wyatt R. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J. Virol. 76 7 (2002) 3511-3521
22. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R.M., Plonk K., Staats H.F., Ortel T.L., Liao H.X., and Alam S.M. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308 5730 (2005) 1906-1908
23. Heppner Jr. D.G., Kester K.E., Ockenhouse C.F., Tornieporth N., Ofori O., Lyon J.A., Stewart V.A., Dubois P., Lanar D.E., Krzych U., Moris P., Angov E., Cummings J.F., Leach A., Hall B.T., Dutta S., Schwenk R., Hillier C., Barbosa A., Ware L.A., Nair L., Darko C.A., Withers M.R., Ogutu B., Polhemus M.E., Fukuda M., Pichyangkul S., Gettyacamin M., Diggs C., Soisson L., Milman J., Dubois M.C., Garcon N., Tucker K., Wittes J., Plowe C.V., Thera M.A., Duombo O.K., Pau M.G., Goudsmit J., Ballou W.R., and Cohen J. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23 17-18 (2005) 2243-2250
24. Ho J., MacDonald K.S., and Barber B.H. Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraint. Vaccine 20 7-8 (2002) 1169-1180
25. Kirnbauer R., Booy F., Cheng N., Lowy D.R., and Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U. S. A. 89 24 (1992) 12180-12184
26. Koch M., Pancera M., Kwong P.D., Kolchinsky P., Grundner C., Wang L., Hendrickson W.A., Sodroski J., and Wyatt R. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313 2 (2003) 387-400
27. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., Chiacchierini L.M., and Jansen K.U. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347 21 (2002) 1645-1651
28. Li Y., Svehla K., Mathy N.L., Voss G., Mascola J.R., and Wyatt R. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J. Virol. 80 3 (2006) 1414-1426
29. Li, Y., Svehla, K., Welcher, B., Phogat, S., Tang, M., Louder, M., Migueles, S., Xueling, Phogat, A., Doria-Rose, N., Shaw, G., Connors, M., Mascola, J., Wyatt, R., in preparation. Strategies for mapping the neutralization specificities in complex, polyclonal neutralizing HIV-1 anti-sera.
30. Liang X., Munshi S., Shendure J., Mark III G., Davies M.E., Freed D.C., Montefiori D.C., and Shiver J.W. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine 17 22 (1999) 2862-2872
31. Lowe R.S., Brown D.R., Bryan J.T., Cook J.C., George H.A., Hofmann K.J., Hurni W.M., Joyce J.G., Lehman E.D., Markus H.Z., Neeper M.P., Schultz L.D., Shaw A.R., and Jansen K.U. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J. Infect. Dis. 176 5 (1997) 1141-1145
32. Mahoney F.J., and Kane M. Hepatitis B vaccine. In: Plotkin O. (Ed). Vaccines (1999) 3rd ed
33. Mangold C.M., Unckell F., Werr M., and Streeck R.E. Analysis of intermolecular disulfide bonds and free sulfhydryl groups in hepatitis B surface antigen particles. Arch. Virol. 142 11 (1997) 2257-2267
34. Mascola J.R., Louder M.K., Winter C., Prabhakara R., De Rosa S.C., Douek D.C., Hill B.J., Gabuzda D., and Roederer M. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J. Virol. 76 10 (2002) 4810-4821
35. McAleer W.J., Buynak E.B., Maigetter R.Z., Wampler D.E., Miller W.J., and Hilleman M.R. Human hepatitis B vaccine from recombinant yeast. Nature 307 5947 (1984) 178-180
36. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., and Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67 11 (1993) 6642-6647
37. Muster T., Guinea R., Trkola A., Purtscher M., Klima A., Steindl F., Palese P., and Katinger H. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 68 6 (1994) 4031-4034
38. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., and Kwong P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78 19 (2004) 10724-10737
39. Pancera M., and Wyatt R. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 332 1 (2005) 145-156
40. Pantaleo G., and Koup R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 10 8 (2004) 806-810
41. Phogat S., and Wyatt R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr. Pharm. Des. 13 2 (2007) 213-227
42. Phogat S., Wyatt R.T., and Karlsson Hedestam G.B. Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J. Intern. Med. 262 1 (2007) 26-43
43. Piza A.T., Pieri K.M., Lusa G.M., Caporale G.M., Terreran M.T., Machado L.A., and Zanetti C.R. Effect of the contents and form of rabies glycoprotein on the potency of rabies vaccination in cattle. Mem. Inst. Oswaldo Cruz 97 2 (2002) 265-268
44. Plotkin S.A. Vaccines, vaccination, and vaccinology. J. Infect. Dis. 187 9 (2003) 1349-1359
45. Salzwedel K., West J.T., and Hunter E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 73 3 (1999) 2469-2480
46. Schirmbeck R., Bohm W., and Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 39 1-2 (1996) 111-119
47. Shu Y., Winfrey S., Yang Z.Y., Xu L., Rao S.S., Srivastava I., Barnett S.W., Nabel G.J., and Mascola J.R. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 25 8 (2007) 1398-1408
48. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., and Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 17 18 (2001) 1757-1765
49. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., Wellde B.T., Garcon N., Krzych U., and Marchand M. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336 2 (1997) 86-91
50. Xiao Y., Zhao Y., Lu Y., and Chen Y.H. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody. Immunol. Invest. 29 1 (2000) 41-50
51. Zinkernagel R.M., Bachmann M.F., Kundig T.M., Oehen S., Pirchet H., and Hengartner H. On immunological memory. Annu. Rev. Immunol. 14 (1996) 333-367
52. Zinkernagel R.M., LaMarre A., Ciurea A., Hunziker L., Ochsenbein A.F., McCoy K.D., Fehr T., Bachmann M.F., Kalinke U., and Hengartner H. Neutralizing antiviral antibody responses. Adv. Immunol. 79 (2001) 1-53